Introduction
Despite recent advances in the treatment of malignant gliomas, the prognosis for patients suffering from this disease continues to be poor. [1] [2] [3] Current therapies involve the use of surgery, radiotherapy, and chemotherapy, but these measures are inadequate due to the significant morbidity associated with these procedures, the infiltrative nature of gliomas, and the development of drug resistance. [4] [5] [6] The challenges of malignant gliomas are unique given the immuno-privileged status of the central nervous system and the confined and sensitive nature of the tumor environment. A novel approach to the treatment of these tumors is the use of virus-based gene therapeutic vectors. The aim of these approaches is to transduce tumors with genes that can aid in the specific destruction of tumor cells. For example, an antitumor immune reac-9L cell proliferation with more limited cell killing. Nevertheless, both vectors supported widespread killing of uninfected cells in the presence of GCV following low multiplicity infections, indicating that vector cytotoxicity did not preempt the production of vector-encoded TK enzyme necessary for the killing of uninfected cells by the HSV-tk/GCV bystander effect. Although an SOZ.1-related vector (SHZ.2) caused tumor cell necrosis in vivo, injection of SHZ.2 at multiple coordinates thoughout the tumor followed by GCV administration failed to prolong markedly the survival of tumorbearing rats. In contrast, a single injection of T.1 produced a life-extending response to GCV. These results indicate that vector cytotoxicity can limit the efficacy of HSV-tk/GCV treatment in vivo, which may be due to premature termination of tk gene expression with attendant abortion of the bystander effect. Gene Therapy (2000) 7, 1483-1490.
tion may be triggered upon delivery of immunostimulatory gene products although immunosuppressive substances commonly secreted by gliomas 7, 8 may hinder this process. Another strategy involves blocking DNA synthesis through the delivery of 'suicide genes' such as those encoding herpes simplex virus thymidine kinase (HSV-TK), cytosine deaminase (CD), or cytochrome p450 2B1. The products of these genes have the ability to convert certain nontoxic pro-drugs to activated forms which interfere with DNA synthesis. Most cells in the central nervous system are nonreplicating and terminally differentiated suggesting that local gene therapy leading to the cessation of DNA synthesis should be largely tumor cell specific.
Previous experiments using various viral vectors to deliver the HSVtk gene as part of a suicide gene therapy strategy have yielded generally positive results in a number of glioma models. [9] [10] [11] [12] The HSV-TK protein phosphorylates the nontoxic pro-drug ganciclovir (GCV), which results in the generation of a defective nucleoside analogue. This product, when incorporated into cellular DNA during replication, leads to DNA chain termination and selective killing of dividing cells. Of particular interest in this strategy is the ability of the defective nucleoside analogue to be passed to cells that are in physical contact with the GCV-converting cells. This leads to widespread killing of both the transduced cells and neighboring cells, a phenomenon referred to as the 'bystander effect'. 13 The bystander effect allows the possibility of complete tumor eradication even at relatively low levels of target cell transduction.
In this report, we examined the utility of replicationdefective mutant HSV-1 vectors for gene therapeutic approaches to malignant gliomas. Defective vectors have been produced which can safely transduce various regions of the brain with minimal toxicity for the host cell.
14 These vectors are based upon an HSV-1 (KOS) mutant, d120, which is deleted for both copies of the essential immediate-early (IE) gene ICP4. 15 The deletion of this gene, whose product is a major transactivator of HSV-1 transcription, results in a vector backbone that produces other proteins of the IE temporal class, but genes of the early and late classes are dramatically reduced in expression. 16 Promoters of the IE type can be used to express transiently transgenes at high levels. 17 We have derived a replication-deficient HSV-1 vector from d120 that uses the strong IE promoter of the ICP4 gene to drive expression of the HSVtk gene (SOZ.1) and have tested this vector as a therapeutic agent in a rat gliosarcoma model. We found that SOZ.1 was toxic for 9L gliosarcoma cells, yet supported enhanced tumor cell killing in the presence of GCV in vitro. In vivo experiments indicated, however, that viral cytotoxicity limited the efficacy of the HSV-TK/GCV suicide system. By deleting two additional IE genes, those encoding ICP22 and ICP27, vectors displaying substantially reduced cytotoxicity in vitro were created. 18, 19 These triple IE gene-deficient vectors showed superior performance in prolonging the survival of 9L tumor-bearing rats in a GCV-dependent manner.
Results

Recombinant viruses
Vectors SOZ.1, THZ.1, T.1 and TOZ.1 used in this work ( Figure 1 ) have been described previously. 18 Briefly, all 18, 19, 22 Vector cytotoxicity Cell viability assays were performed to assess the toxicity of viral mutants deleted for one or three IE genes. Rat gliosarcoma 9L cells which are highly susceptible to infection with replication-incompetent ICP4 − HSV-1 mutants 18 were infected with the single or triple IE gene deletion viruses SOZ.1, T.1 and TOZ.1 at multiplicities of infection (MOIs) of 0.1, 1 and 10. Growth rates were measured by MTT assay, transduction rates and morphologies of SOZ.1-and TOZ.1-infected cells analyzed by Xgal staining for ␤-galactosidase activity, and apoptosis examined by a fluorescent TUNEL assay.
Infection of 9L cells with SOZ.1 at an MOI of 10 resulted in cell loss by 3 days post-infection (p.i.) ( Figure  2 ), at which time a majority of the cells (98%, Figure 3 ) were undergoing apoptosis. In contrast, while infection 
Efficacy of GCV treatment
To explore the effect of virus cytotoxicity on cell killing in the presence of ganciclovir (GCV), 9L cells were infected at different MOIs with SOZ.1 or T.1, and exposed to GCV for 3 days. While SOZ.1 infection again reduced the number of viable cells more than T.1 infection at the higher MOIs without GCV, no clear differences were observed at any MOI in the presence of GCV Gene Therapy ( Figure 5 ). Thus, no viable cells remained in the GCVtreated cultures infected at the higher MOIs, and similar fractions of the cells remained at the lowest MOI. In the absence of GCV, approximately 90% of the cells infected at the lowest MOI with either virus survived, as before (Figure 2 ), but a strong bystander effect of GCV treatment was apparent as far larger fractions of these surviving cells were killed by exposure to GCV (approximately 90%) than would be expected if TK-activated GCV killed only infected cells (Ͻ10% at an MOI of 0.1). These results indicated that GCV treatment of HSVtk-transduced cells can be effective in vitro whether or not the vector is cytotoxic.
Therapeutic value of virus cytotoxicity
Animal survival experiments were performed to determine whether SOZ.1 alone or in combination with GCV treatment could impair tumor growth. Rat intracranial implants of 9L cells were injected after 5 days with 1 × 10 7 p.f.u. of SOZ.1, and GCV was administered daily for 7 days to half the animals by intraperitoneal injection. As illustrated in Figure 6 , SOZ.1 failed to prolong the survival of tumor-bearing rats compared with untreated controls, and GCV administration did not alter the outcome. The lack of GCV effect was consistent with the interpretation that the intended source of HSV-TK, the fraction of tumor cells transduced by the vector, had been rapidly eliminated by the cytotoxicity of the vector, thus precluding the development of a bystander effect. At the same time, the infection rate was apparently insufficient to achieve a significant delay in tumor growth by viral cytotoxicity alone.
To examine virus cytotoxicity in vivo, the SOZ.1-related vector SHZ.2 (see Figure 1 ) was injected into intracranial 9L tumors and contralateral control sites 7 days after tumor cell implantation (3 × 10 7 p.f.u.). Histopathologic analysis of sections taken 2 days later showed tumor cell necrosis in the immediate area of injection (Figure 7b ; area of infection was too limited to control tumor growth in the absence of a bystander effect. The procedure, using a single injection of replication-incompetent virus, left normal surrounding cells unaffected.
The lack of GCV effect on the survival of tumor-bearing, SOZ.1-injected animals ( Figure 6 ) and the demonstrated tumor cell necrosis at the sites of SHZ.2 injection (Figure 7b ) supported the suggestion that virus cytotoxicity interferes with the production of HSV-TK and thus with the development of a bystander effect. As a potential alternative to the bystander effect, we examined whether high-density delivery of one of these cytotoxic vectors (SHZ.2) could be an effective antitumor weapon. Intracranial 9L tumors approximately 8 mm 3 in size (7 days after implantation) were injected at 15 coordinates with the same total amount of virus as applied earlier by single injection (3 × 10 7 p.f.u.), and sections were examined 2 days later. As shown in Figure 7c , multipoint injection caused necrosis of the entire tumor area without damage to the adjacent normal brain tissue. Thus, the virus appeared to be capable of eliminating the bulk of the tumor when administered at high density. Nevertheless, multipoint injection of SHZ.2 with or without GCV treatment failed to extend the life-span of tumor-bearing rats by more than a few days at best (Table 1, 7 days after implantation), even when performed at an early stage of tumor development (3 days after implantation; Table 1 ). From these results we concluded that the cytotoxicity of single IE-gene deletion viruses (SOZ.1, SHZ.2) had no practical therapeutic value and that these vectors were ineffective agents of suicide gene therapy.
Therapeutic value of a less cytotoxic virus
The preceding results suggested that less cytotoxic vectors such as T.1 would be more effective tools for HSV-TK/GCV therapy than such highly cytotoxic vectors as SOZ.1. To test this suggestion, intracranial 9L tumors were injected with T.1 virus 5 days after implantation and exposed to GCV treatment; virus delivery was by a single injection of 1 × 10 7 p.f.u. and GCV was administered intraperitoneally on 10 successive days. Figure 8 shows that while the individual and median survival times of medium-and T.1-injected animals were similar, GCV administration now provided a clear benefit (P Ͻ 0.05), delaying the demise of T.1-injected animals by up to 15 days or more for the longest survivors. This result confirmed that vector cytotoxicity limited the effectiveness of HSV-based antitumor suicide gene therapy, presumably by shutting down the sites of HSV-TK production, and demonstrated that this limitation could be resolved by deleting a combination of immediate-early genes from the vector. In all, this study showed that bystander killing is a more effective mechanism against intracranial 9L tumors than vector cytotoxicity, at least when the vector is replication incompetent to prevent uncontrolled virus spread.
Discussion
The hit-and-run mechanism by which cytocidal viruses amplify while destroying the host cell might be an ideal antitumor weapon if the infectious specificity of the virus could be restricted to the tumor cell. Many viruses require active cell division for replication, thus favoring tumor cells over terminally differentiated normal cells as targets, but virus release into the circulation is not easily contained and can cause serious side-effects. Although replication-competent vectors are theoretically more efficient in infecting the majority of tumor cells in a solid tumor than replication-defective vectors, this remains to be formally demonstrated. Replication-defective vectors offer a better safety profile because they are not amplified in vivo and do not readily spread beyond the initial site of infection, especially when injected into a region with limited access to the circulation. However, this inability to spread also allows tumor cells to escape infection, thus limiting the effectiveness of replication-defective cytotoxic vectors. This limitation may be obviated by the use of vectors that supply gene products such as HSV-TK that are capable of expanding the field of tumor cell killing to noninfected cells.
We have compared two mechanisms of virus-dependent tumor destruction using replication-incompetent HSV vectors and have shown that only one is effective, but not in combination with the other. To evaluate the first mechanism, direct virus-mediated cell killing, cytotoxic virus was distributed throughout small tumors by injection at numerous sites. While this procedure resulted in widespread tumor cell necrosis, lethal tumor outgrowth was not substantially delayed indicating that a portion of the tumor cells had escaped infection. The second mechanism did not require complete infection of the tumor mass, but instead relied on the spread of viral TK-activated GCV to reach uninfected tumor cells. However, when GCV was administered after intra-tumoral delivery of a pro-drug activating but cytotoxic HSVtk gene vector, no significant increase in animal survival was observed. On the other hand, GCV had a markedly beneficial effect on animals injected with a less cytotoxic TK vector, indicating that vector cytotoxicity could limit the production of TK enzyme and hence the production and spread of toxic GCV. We concluded that vector cytotoxicity interfered with effective HSV-TK/GCV therapy using replication-defective TK vectors and that the deletion of multiple viral IE genes reduced this deficiency.
It has been repeatedly demonstrated in the past that HSV vector cytotoxicity precludes prolonged transgene expression. 18, 19, 22 Several of the immediate-early genes of HSV are cytotoxic when expressed separately 20 and their removal from the virus genome allows protracted synthesis of viral and transgene products provided that the promoters controlling these genes function independently of IE proteins, in particular of the transcriptional transactivator ICP4. The IE promoters are convenient examples of IE protein-independent promoters 17 and we used the ICP4 promoter in our vectors to direct HSVtk gene expression. In agreement with previous studies of HSV vector toxicity and transgene expression in different cell types, 18, 19, [22] [23] [24] we observed that removal of the ICP22 and ICP27 genes from an ICP4-deficient vector background improved the response of vector-injected 9L gliosarcomas to GCV.
Aside from the cytotoxic IE genes, HSV-1 infection also introduces into the host cell the U L 41 vhs gene product, a component of the viral tegument causing host proteinsynthesis shut-off which may contribute to the cytotoxicity of replication-deficient HSV vectors. 25 Our vectors T.1 and TOZ.1 differed exclusively in the U L 41 locus, which was wild-type in T.1, but disrupted by a lacZ expression cassette in TOZ.1. These two vectors had similar effects in our apoptosis assay, suggesting that the vhs gene product contributes little to the cytotoxicity of replicationdefective HSV vectors, in agreement with previous observations. 18, 20, 21 Accordingly, inactivation of the U L 41 locus is not a critical step in HSV vector design although the locus is a convenient site for the insertion of therapeutic transgenes. 26 Our in vitro studies showed that infection of 9L cells with the single IE gene deletion vector SOZ.1 at high MOI, leading to infection of a majority of the cells, caused a net loss of viable cells as early as 2 days p.i., pointing not merely to inhibition of cell proliferation, but to rapid cell killing. Indeed, a large fraction of these cells were undergoing apoptosis 3 days after infection and infected cells displayed morphological changes indicative of severe stress. Nevertheless, a sizable bystander effect was observed in SOZ.1-infected cultures, suggesting that HSV-TK was synthesized early enough relative to virusmediated cell death to allow adequate production and distribution of toxic GCV. Thus, although vector cytotoxicity appeared to preclude a significant HSV-TK/GCV antitumor effect, it was compatible with HSV-TK/GCV bystander killing in vitro. This discrepancy may relate to the effective availability of GCV, which is instantly adequate in vitro, but not when the pro-drug is administered by i.p. injection in vivo.
Unlike the experimental animals used in this work, a large fraction of the human population has been previously exposed to HSV infection, which raises the likelihood of local inflammation around the tumor site in response to virus injection. With other vector systems delivering HSV-TK to 9L tumors, correlations have been noted between nonspecific local inflammation and the development of a specific antitumor immune response. 27 This suggests the possibility that the local therapeutic effects of HSV-based TK vectors in combination with GCV may be enhanced by pre-exposure to HSV. While an anti-HSV response is generally undesirable in HSVbased gene therapy applications, the possibility that it positively contributes to antitumor therapy deserves further experimental scrutiny. On the other hand, a recent study reported widespread chronic brain inflammation, vector distribution, and detection of TK protein in animals cured of experimental gliomas by local injection of replication-incompetent adenoviral TK vectors in combination with systemic GCV treatment. 28 Hence, the occurrence of acute and chronic inflammation and their effects in response to HSV-based TK/GCV therapy are important areas of future investigation.
In summary, our results show that replication-defective HSV vectors become better tools for HSV-TK/GCV therapy when their cytotoxicity is reduced, which can be accomplished by a combination of IE gene deletions. While vector cytotoxicity did not abolish the HSV-TK bystander effect in vitro, it did in vivo, presumably because the transduced effector cells were incapacitated before sufficient amounts of toxic GCV metabolite could be produced and exported. Future directions to improve the success of tumor treatment using HSV-based gene therapy vectors include optimizing the relative timing of vector and GCV administration, exploring the effects of previous exposure to HSV, and the development of vectors that use tumor cell-specific receptors for infection and express transgenes that improve bystander killing. For example, we have recently demonstrated in animal models that radiosurgery combined with vector-directed production of tumor necrosis factor alpha can improve the efficacy of HSV-TK/GCV therapy for glioblastoma 34 and that expression of connexin 43 from an HSV-TK vector improves the GCV bystander effect in tumors with reduced intercellular communication through gap junctions. 29 These findings, together with our present results, suggest that multi-modal therapies combining conventional treatments with the use of highly defective vectors capable of delivering multiple therapeutic gene products may provide unparalleled new opportunities for effective clinical treatment of recurrent glioma.
Materials and methods
Cell culture and virus production Vero African green monkey kidney cells (CCL81; ATCC, Rockville, MD, USA) and Vero-derived E5 15 and 7B cells 30 were maintained in MEM (LTI, Gaithersburg, MD, USA) supplemented with glutamine, antibiotics (PSN), and 10% fetal bovine serum (all from LTI). 9L rat gliosarcoma cells (kindly provided by Dr KM Culver, NIH, Bethesda, MD, USA) were maintained in DMEM supplemented with glutamine, antibiotics, and 10% fetal bovine serum. HSV-1 stocks were prepared by infecting E5 or 7B cells, which supply the ICP4 protein, respectively, the ICP4 and ICP27 proteins in trans, 15, 30 at a multiplicity of 0.03. Infected cells were harvested when a 100% cytopathic effect was evident and subjected to three cycles of freezethawing (−80°C/37°C) and a single burst of sonication. The virus was then separated from cell debris by centrifugation. Virus stocks were aliquoted into 2 ml cryogenic tubes (Corning Glass Works, Corning, NY, USA) and stored at −80°C. Final titers averaged 2 × 10 8 to 2 × 10 9 p.f.u./ml.
Construction of recombinant HSV-1 vectors SHZ.2 18 was created by Cre-lox recombination 31 of a human cytomegalovirus (HCMV) IE promoter (IEp)-lacZ expression cassette together with an HSV-1 ICP4 promoter (ICP4p)-HSVtk cassette into the U L 23 (HSVtk) locus of a virus backbone based on d120, a KOS strain mutant deleted for both copies of the ICP4 gene 15 ( Figure 1 ). SOZ.1 was created via homologous recombination replacing a U L 41 SmaI fragment of S4TK, a U L 24 − :ICP4p-tk derivative of d120, 26 with an ICP0p-lacZ expression cassette. 18 THZ.1 had the S4TK backbone with the HCMV IEp-lacZ cassette replacing a portion of the ICP22 gene and the ICP27 gene inactivated by a deletion. 18 T.1 was derived from THZ.1 by removal of the lacZ gene, leaving behind within the ICP22 gene the upstream and downstream regulatory sequences of the lacZ cassette. 18 TOZ.1 was produced as a cross between SOZ.1 and T.1. 18 All marker transfer reactions were carried out by standard calcium phosphate transfection of 5 g viral DNA and 1 g linear recombination plasmid. 30 Viral crosses were performed by co-infection of monolayers of 7B cells 30 at an MOI of 5 for each virus followed by harvesting at 18 h p.i. All resultant viral mutants were purified by three rounds of limiting dilution and their genome structures were verified by Southern blotting.
In vitro cytotoxicity assays
In vitro cytotoxicity was examined by standard MTT assay. 32 Cells were infected in suspension for 1 h at different MOIs and dispensed into 96-well, flat-bottomed microtiter plates (Becton Dickinson, Franklin Lakes, NJ, USA) at a concentration of 1 × 10 4 cells in 100 l per well. The cells were incubated with or without GCV (10 g/ml) at 37°C in 5% CO 2 . On each day after infection (Figure 2 ) or 3 days p.i. (Figure 5 ), 25 l 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) solution (5 mg/ml; Sigma Chemicals, St Louis, MO, USA) was added to each well and incubation at 37°C in 5% CO 2 was continued for 30 min. Supernatants were removed and 100 l dimethylsulfoxide was added to each well. After another 30 min incubation, absorbances were measured using an EL312e plate reader equipped with a 570 nm filter (Biotek Instruments, Winooski, VT, USA).
Apoptosis was visualized by a fluorescent TUNEL assay using the manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN, USA).
